Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.
Vous n'êtes pas connecté
Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.
Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.
Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
WELL's seniors housing operating portfolio is set to benefit from the aging population and rising healthcare spending. However, high competition is a...
WELL's seniors housing operating portfolio is set to benefit from the aging population and rising healthcare spending. However, high competition is a...
Rising healthcare spending and aging population aid Ventas' senior housing operating portfolio. However, tenant concentration and high interest rates...
AXON benefits from strength across its businesses, product introductions and complementary acquisitions. Rising costs and expenses may hurt its...